NCT07264010Not yet recruitingPhase 2/3
Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study
Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for Measurable Residual Disease Persisting Acute Myeloid Leukemia: a Prospective, Single-arm, Multicenter Clinical Study
Source: ClinicalTrials.gov · Last updated 4 Dec 2025
Brief summary (registry, in English)
The purpose of this study is to explore the efficacy and safety of sorafenib combined with venetoclax as pre-emptive therapy strategy for measurable residual disease persisting acute myeloid leukemia.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 87 (estimated)
- First submitted
- 23 Nov 2025
- Start date
- 1 Dec 2025
- Primary completion date
- 30 Dec 2026
- Lead sponsor
- Nanfang Hospital, Southern Medical University
- Diseases
- Acute myeloid leukemia
- NCT number
- NCT07264010
What you commit to
- Study type: Interventional · Phase 2/3
- Planned participants: 87
- From 1 Dec 2025 to the primary completion date, 30 Dec 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Uncontrolled infection or grade 3-4 graft-versus-host disease (GVHD);
- Allergies or contraindications to any of the drugs involved in the protocol;
- Severe organ dysfunction such as heart, liver, kidneys, lungs, etc.
Other
- Acute promyelocytic leukemia;
- Hematological non-remisssion or recurrence;
Who the study is looking for
- Voluntary signing of informed consent form;
- Liver and kidney function: Blood bilirubin ≤ 35 μ mol/L, AST/ALT \< 2 times the upper limit of normal, blood creatinine ≤ 150 μ mol/L;
- Normal heart function (EF ≥ 50%, NYHA I/II);
- Physical condition score 0-2 (ECOG score);
- Non pregnant and lactating women. For all women of childbearing age, a pregnancy test must be conducted to determine hCG levels in order to exclude pregnancy status;
- For all men of childbearing age, contraceptive measures must be taken during sorafenib treatment until 3 months after discontinuation.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.